SecBot SecBot
SECBOTREPLAY Home › Report › BCRX

BCRX · BioCryst held its 2026 Annual Meeting on June 11, 2026, where…

BIOCRYST PHARMACEUTICALS INC · 8-K filed Jun 12, 2026 at 16:10 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 12, 2026 at 16:10 ET

BioCryst held its 2026 Annual Meeting on June 11, 2026, where shareholders approved an amendment to the Stock Incentive Plan to increase shares available by 7 million, ratified Ernst & Young as auditor, and elected three directors. The plan amendment passed with 119.8 million votes for and 63.3 million against (65.4% approval of votes cast). This is a routine governance event with no material financial impact, as the additional shares simply replenish the equity compensation pool for future awards to employees and directors.

  • Shareholders approved an amendment to the Stock Incentive Plan to increase the number of shares available for issuance by 7,000,000 shares.
  • Total shares available under the Plan as of April 20, 2026, was 61,000,333 (including 46,287,133 already issued, 7,713,200 available, and the 7,000,000 increase).
  • Maximum shares issuable over the Plan's term is 88,090,000.
  • The Plan includes a 12-month minimum vesting period for awards (with exceptions for death, disability, or change in control, and for up to 5% of shares).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access